New Labeling May Signal Trouble for Vivus' Qnexa
By Mari Serebrov
Monday, March 7, 2011
WASHINGTON The FDA's call for more explicit labeling about birth defects for topiramate is not the news Vivus Inc. wanted to hear.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.